Scienture Holdings, Inc.

SCNX

US80880X2036

Pharmaceuticals

Market Closed - Nasdaq 16:30:00 2026-11-06 EST			5-day change	1st Jan Change
3.125 ^USD	+0.81%		-2.95%	-75.49%

10-28	Scienture Holdings, Inc. - Shareholder/Analyst Call
10-13	Scienture Holdings, Inc. Reports Preliminary, Unaudited Revenue Results for the Third Quarter Ended September 30, 2026	CI

Top Midday Decliners

Published on 08/14/2025 at 01:56 pm EDT

MT Newswires

This article is reserved for our members.

Continue with Google Continue with Apple Continue with LinkedIn

or by email

Continue with an email.

Latest news about Scienture Holdings, Inc.

10-28	Scienture Holdings, Inc. - Shareholder/Analyst Call
10-13	Scienture Holdings, Inc. Reports Preliminary, Unaudited Revenue Results for the Third Quarter Ended September 30, 2026	CI
10-02	Scienture Holdings, Inc. Announces Arbli? Added To Formularies At Three U.S. Pediatric Academic Medical Centers And Hospitals	CI
10-01	Top Premarket Decliners	MT
08-13	Scienture Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-12	Scienture Holdings Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy Nasal Spray 10 Mg	CI
07-09	Scienture Holdings, Inc. Completes Manufacturing of Commercial Launch Inventory and Begins Shipments of Rezenopy Nasal Spray 10 Mg to U.S. Pharmaceutical Wholesalers	CI
06-18	Scienture Holdings Expands Arbli Payor Coverage and Commercial Access	CI
06-09	Scienture Holdings, Inc. Secures Formulary Coverage for REZENOPYTM with Large National Health Plan and Expands Commercial Team	CI
06-02	Scienture Secures US Patent Protection for Rezenopy Through 2041	MT
05-29	Scienture - Eric Sherb resigns as CFO effective May 26, 2026	RE
05-29	Scienture Holdings, Inc. Announces CFO Changes, Effective May 26, 2026	CI
05-15	Scienture Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Scienture secures $11.0 million in non-dilutive debt financing to accelerate growth of approved product portfolio and advancement of research and development pipeline	RE
05-07	Scienture Holdings, Inc. Secures $11 Million in Non-Dilutive Debt Financing	CI

Chart Scienture Holdings, Inc.

Duration

Period

SCNX: Dynamic Chart

Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.

Employees

Sector

Pharmaceuticals

More about the company